Eli Lilly (LLY) stock rose slightly early Thursday after the drug giant reported adjusted earnings of $5.32 per share on $13.53 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?On average, analysts polled by FactSet expected Lilly to earn $5.06 per share and report $13.55 billion in sales. In the year-earlier period, the pharma company reported earnings of $2.49 per share on $9.35 billion in sales.
Weight-loss drug Zepbound generated $1.91 billion, while diabetes treatment Mounjaro brought in $3.53 billion. Analysts called for a respective $1.99 billion and $3.63 billion in sales.
For the year, Eli Lilly guided to adjusted EPS of $22.50-$24 on revenue of $58 billion-$61 billion, with the midpoints both above consensus. The Street called for adjusted earnings of $22.76 per share and $58.77 billion in sales.
In premarket trades on the stock market today, Eli Lilly stock rose 1.2%. Shares are consolidating with a buy point at 972.53, according to MarketSurge. On Wednesday, LLY stock closed above its 200-day line for the first time in nearly three months.
More to follow.
YOU MAY ALSO LIKE:
Novo Surges As Ozempic Drives Fourth-Quarter Beat. But Supply Shortages Expected.
How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。